Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients’ quality of life over time. It causes neuropsychiatric disorders and neurocognitive impairment in roughly 50 percent of patients. The drug is associated with abnormal lipid levels in blood plasma, but the molecular mechanisms responsible for negative clinical observations are unknown.
Conversion Practices Tied to Greater Symptoms of PTSD, Suicidality
Exposure to conversion practices was associated with increases in several mental health symptoms for sexual and gender minority individuals, according to a cross-sectional study. The
October 1, 2024